EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.

Journal: Journal of cardiac failure
Published Date: Dec 7, 2023

Abstract

BACKGROUND: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), an increasingly recognized cause of heart failure (HF), often remains undiagnosed until later stages of the disease.

Authors

  • Adam Castaño
    Pfizer, Inc., New York, NY, USA.
  • Stephen B Heitner
    Oregon Health and Science University, Knight Cardiovascular Institute Hypertrophic Cardiomyopathy and Cardiogenetics Centers, Portland (S.B.H., M.C.M., K.E.).
  • Ahmad Masri
    The Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.
  • Ahsan Huda
    Pfizer Inc., New York, NY, USA.
  • Veena Calambur
    Drexel University, Philadelphia, PA, USA.
  • Marianna Bruno
    Pfizer, Inc., New York, NY, USA.
  • Jennifer Schumacher
    Pfizer, Inc., New York, NY, USA.
  • Birol Emir
    Pfizer Inc, New York, New York.
  • Catherine Isherwood
    Pfizer Inc, New York, New York.
  • Sanjiv J Shah
    Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Keywords

External Resources

Popular Topics
Recent Journals